Detalles de la búsqueda
1.
Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials.
Oncologist
; 27(3): e286-e293, 2022 03 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274718
2.
Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial.
Lancet Oncol
; 22(2): 190-197, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33450184
3.
The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data.
Qual Life Res
; 30(2): 445-454, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32851601
4.
Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.
Oncologist
; 24(7): e510-e517, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30478189
5.
The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis.
Oncologist
; 24(7): e501-e509, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30952820
6.
Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
Mol Carcinog
; 58(11): 1960-1973, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31355511
7.
Immediate Versus Deferred Systemic Therapy in Patients With Mesothelioma.
Clin Lung Cancer
; 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38825405
8.
Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
Clin Lung Cancer
; 24(1): 40-50, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36270866
9.
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.
Nat Med
; 29(10): 2559-2569, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37814061
10.
Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence.
Cancer Treat Res Commun
; 37: 100774, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37979334
11.
Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies.
JTO Clin Res Rep
; 4(10): 100562, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37744308
12.
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.
JAMA Netw Open
; 6(7): e2325332, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37490292
13.
Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection.
JTO Clin Res Rep
; 3(2): 100259, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35112092
14.
Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data.
Clin Lung Cancer
; 23(2): e154-e164, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34688531
15.
Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre.
Clin Lung Cancer
; 23(1): e43-e53, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34531139
16.
Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.
Cancer Treat Res Commun
; 31: 100534, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35278845
17.
CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
J Thorac Oncol
; 17(3): 434-445, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34800700
18.
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLC.
Lung Cancer
; 171: 42-46, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35907387
19.
Genetic associations with sporadic neuroendocrine tumor risk.
Carcinogenesis
; 32(8): 1216-22, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21606320
20.
The effect of prior cancer on non-small cell lung cancer trial eligibility.
Cancer Med
; 10(14): 4814-4822, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34145985